M Anthony Moody

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages
    M Anthony Moody
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA
    J Virol 86:7496-507. 2012
  2. ncbi H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination
    M Anthony Moody
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 6:e25797. 2011
  3. ncbi Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines
    M Anthony Moody
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Exp Med 207:763-76. 2010
  4. ncbi Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Immunity 38:176-86. 2013
  5. ncbi Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region
    Laurent Verkoczy
    Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 4:e7215. 2009
  6. ncbi Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting
    Lynn Morris
    Duke Human Vaccine Institute and Departments of Medicine, Surgery and Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America
    PLoS ONE 6:e23532. 2011
  7. ncbi Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
    J Exp Med 208:2237-49. 2011
  8. ncbi Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins
    Feng Gao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Virology 394:91-8. 2009
  9. ncbi HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design
    Mattia Bonsignori
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Trends Microbiol 20:532-9. 2012
  10. ncbi Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family
    Mattia Bonsignori
    Duke University Medical Center, Durham, North Carolina, USA
    J Virol 86:11521-32. 2012

Detail Information

Publications26

  1. ncbi HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages
    M Anthony Moody
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA
    J Virol 86:7496-507. 2012
    ..Improved vaccination strategies will be needed to drive persistent stimulation of antibody clonal lineages to induce affinity maturation that results in highly mutated HIV-1 Env-reactive antibodies...
  2. ncbi H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination
    M Anthony Moody
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 6:e25797. 2011
    ..In contrast, a history of recent seasonal trivalent vaccine in younger adults was not associated with protection...
  3. ncbi Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines
    M Anthony Moody
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Exp Med 207:763-76. 2010
    ..The release of these beta-chemokines explains both the specificity for R5 HIV-1 and the activity of these mAbs in PBMC cultures containing both primary lymphocytes and monocytes...
  4. ncbi Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Immunity 38:176-86. 2013
    ..Variation may signal sites of HIV-1 envelope vulnerability, providing vaccine designers with new options...
  5. ncbi Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region
    Laurent Verkoczy
    Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 4:e7215. 2009
    ..These data suggest that low avidity, non-paratopic interactions between the gp41 MPER and membrane Ig on naïve B cells may interfere with or divert bnAb responses...
  6. ncbi Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting
    Lynn Morris
    Duke Human Vaccine Institute and Departments of Medicine, Surgery and Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America
    PLoS ONE 6:e23532. 2011
    ..These data indicate that there are multiple immunogenic targets in the C-terminus of the MPER of HIV-1 gp41 envelope and suggests that gp41 neutralizing epitopes may interact with a restricted set of naive B cells during HIV-1 infection...
  7. ncbi Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
    J Exp Med 208:2237-49. 2011
    ..These data suggest that the majority of gp41-binding antibodies produced after acute HIV-1 infection are cross-reactive responses generated by stimulating memory B cells that have previously been activated by non-HIV-1 antigens...
  8. ncbi Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins
    Feng Gao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Virology 394:91-8. 2009
    ..Nonetheless, such mAbs represent valuable reagents to study the biochemistry and structural biology of Env protein oligomers...
  9. ncbi HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design
    Mattia Bonsignori
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Trends Microbiol 20:532-9. 2012
    ..Strategies are being developed for the analysis of infection and vaccine candidate-induced antibodies, their gene usage, and their maturation pathways such that this information can be used to attempt to guide rational vaccine design...
  10. ncbi Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family
    Mattia Bonsignori
    Duke University Medical Center, Durham, North Carolina, USA
    J Virol 86:11521-32. 2012
    ..The polyclonality and low mutation frequency of these VH1 antibodies reveal fundamental differences in the regulation and maturation of these ADCC-mediating responses compared to VH1 bNAbs...
  11. ncbi HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection
    Mattia Bonsignori
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 183:2708-17. 2009
    ..The inability to generate high titers of long-lived anti-envelope Abs is a major hurdle to overcome for the development of a successful HIV-1 vaccine...
  12. ncbi Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection
    Marc C Levesque
    Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America
    PLoS Med 6:e1000107. 2009
    ..While the effect of HIV-1 on depletion of gut CD4(+) T cells in acute HIV-1 infection is well described, we studied blood and tissue B cells soon after infection to determine the effect of early HIV-1 on these cells...
  13. ncbi High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, 27710, United States
    J Virol Methods 158:171-9. 2009
    ..These Ig gene expression cassettes constitute a highly efficient strategy for rapid expression of Ig genes for high-throughput screening and analysis without cloning...
  14. ncbi Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors
    Mattia Bonsignori
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 85:9998-10009. 2011
    ..Thus, E.A244, B.9021, and AE.CM243 Envs are three potential immunogen candidates for studies aimed at defining strategies to induce V2/V3 conformational epitope-specific antibodies...
  15. ncbi Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection
    S Munir Alam
    Human Vaccine Institute, Box 3258, Duke University Medical Center, MSRBII Bldg, Room 4042, Durham, NC 27710, USA
    J Virol 82:115-25. 2008
    ....
  16. ncbi B cell responses to HIV-1 infection and vaccination: pathways to preventing infection
    Barton F Haynes
    Duke Human Vaccine Institute and the Duke Center for AIDS Research, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
    Trends Mol Med 17:108-16. 2011
    ....
  17. ncbi Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies
    Laurent Verkoczy
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA
    Curr Opin Immunol 23:383-90. 2011
    ....
  18. ncbi Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum
    James Friedman
    Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States
    PLoS ONE 7:e37648. 2012
    ..Therefore, characterization of HIV-specific antibodies produced by B cells in milk could guide the development of vaccines that elicit protective mucosal antibody responses...
  19. ncbi Antibody polyspecificity and neutralization of HIV-1: a hypothesis
    Barton F Haynes
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham NC 27710, USA
    Hum Antibodies 14:59-67. 2005
    ....
  20. ncbi Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual
    Elin S Gray
    Duke Human Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA
    J Virol 85:7719-29. 2011
    ..Our data validate the use of differential sorting to isolate a MAb targeting a specific epitope in the envelope glycoprotein and provided insights into the mechanisms of autologous neutralization escape...
  21. ncbi An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum
    Guido Ferrari
    Duke University Medical Center, Department of Surgery, P O Box 2926, Durham, NC 27710, USA
    J Virol 85:7029-36. 2011
    ..These data demonstrate that the epitope defined by MAb A32 is a major target on gp120 for plasma ADCC activity...
  22. ncbi Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design
    Nancy Gasper-Smith
    Duke Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA
    J Virol 82:7700-10. 2008
    ....
  23. ncbi Primary infection by a human immunodeficiency virus with atypical coreceptor tropism
    Chunlai Jiang
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 85:10669-81. 2011
    ..These results suggest that the ZP6248 T/F virus established an acute in vivo infection by using coreceptor(s) other than CCR5 or CXCR4 or that the CCR5 coreceptor existed in an unusual conformation in this individual...
  24. ncbi Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials
    David C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Infect Dis 206:431-41. 2012
    ..No protection was observed in Thai injection drug users who received AIDSVAX B/E alone (Vax003 trial). We compared the neutralizing antibody response in these 2 trials...
  25. ncbi Antigen-specific B cell detection reagents: use and quality control
    M Anthony Moody
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cytometry A 73:1086-92. 2008
    ..We also present an analysis of strengths and weaknesses of various methods for flow cytometric analysis of antigen-specific B cells...
  26. ncbi Increased expression of anti-apoptosis genes in peripheral blood cells from patients with paroxysmal nocturnal hemoglobinuria
    Matthew M Heeney
    Division of Pediatric Hematology Oncology, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA
    Mol Genet Metab 78:291-4. 2003
    ..Anti-apoptosis gene upregulation may confer resistance to apoptosis in PNH and related disorders, and provide a common compensatory mechanism after bone marrow injury that allows survival and growth of remaining hematopoietic stem cells...